Potential synergistic protection of retinal ganglion cells from axotomy-induced apoptosis by adenoviral administration of glial cell line-derived neurotrophic factor and X-chromosome-linked inhibitor of apoptosis
2002 | journal article; research paper. A publication with affiliation to the University of Göttingen.
Jump to: Cite & Linked | Documents & Media | Details | Version history
Cite this publication
Potential synergistic protection of retinal ganglion cells from axotomy-induced apoptosis by adenoviral administration of glial cell line-derived neurotrophic factor and X-chromosome-linked inhibitor of apoptosis
Straten, G.; Schmeer, C.; Kretz, A.; Gerhardt, E. ; Kugler, S. ; Schulz, J. B. & Gravel, C. et al. (2002)
Neurobiology of Disease, 11(1) pp. 123-133. DOI: https://doi.org/10.1006/nbdi.2002.0543
Documents & Media
Details
- Authors
- Straten, G; Schmeer, C.; Kretz, A.; Gerhardt, Ellen ; Kugler, S. ; Schulz, Joerg B. ; Gravel, C.; Bähr, Mathias ; Isenmann, Stefan
- Abstract
- Following transection of the optic nerve (ON) in the adult rat, retinal ganglion cells (RGCs) undergo degeneration, and within 14 days 85% of axotomized RGCs die by apoptosis. Adenoviral delivery of the mammalian caspase inhibitor X-chromosome-linked inhibitor of apoptosis (Ad.XIAP) to the ON stump leads to expression exclusively in RGCs and rescues 18.9% of the RGCs that would degenerate without treatment. Following adenoviral vector injection into the vitreous body, bioactive glial cell line-derived neurotrophic factor (Ad.GDNF) is expressed in the retina and secreted to rescue 22.8% of lesioned RGCs. Here we report that coadministration of Ad.XIAP retrogradely directed to RGCs and intravitreal Ad.GDNF acts synergistically to protect axotomized RGCs. Combination treatment rescued 47.3% of RGCs that would undergo apoptosis without any treatment as opposed to 37.4% that would be expected if the two treatments acted independently. While without treatment only 15% of axotomized RGCs would survive, combination treatment resulted in survival of 55.4% of the total RGC population. These findings underline the neuroprotective potential of synergistic effects of a combination of different treatment strategies. (C) 2002 Elsevier Science (USA).
- Issue Date
- 2002
- Journal
- Neurobiology of Disease
- ISSN
- 0969-9961